title: [PCSK9 inhibitors reduces LDL cholesterol by 60 percent].
authors.affiliation: Lund University - Clinical Sciences Malmö, Sweden Lund University - Clinical Sciences Malmö, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Nilsson
authors.affiliation: Wallenberg Laboratory - Experimental and Clinical Medicine Göteborg, Sweden Wallenberg Laboratory - Experimental and Clinical Medicine Göteborg, Sweden.
authors.forename: Olov
authors.initials: O
authors.lastname: Wiklund
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000187:drug effects*; D006801:Humans; D000091362:PCSK9 Inhibitors; D012307:Risk Factors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9